BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.
Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
Since joining Eli Lilly’s patent division nearly 20 years ago, Manisha Desai has worked on the procurement and enforcement of patents worldwide.
A shift in Mexico’s examination practice on plant-related patents has caused legal uncertainty, say Daniel Eduardo López and Esteban Rodríguez of Clarke Modet & Co.
Balancing a company’s duty to shareholders with the public responsibility to provide lifesaving treatments is a constant challenge, as Issi Rozen, chief business officer at the Broad Institute of MIT and Harvard, tells LSIPR.
With his interests in IP development, biotechnology innovation policy, and R&D, Luiz Otávio Pimentel, president of Brazil’s patent office, tells LSIPR of his aims to improve the country’s IP performance.
The healthcare industry and governments around the world are turning to precision medicine as an opportunity and a potential saviour. Daniel Lim of Kirkland & Ellis discusses the issues around translating the promise of precision medicine into real world clinical practice.
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.
As a rival to CRISPR in the gene-editing field, zinc finger nuclease technology is making a name for itself. LSIPR hears from Sandy Macrae, CEO of Sangamo Therapeutics, one of the key players in this area.